LDL Receptor-Mediated Endocytosis and Cholesterol Homeostasis

Core Concept

Low-density lipoprotein (LDL) carries cholesterol through the blood. Cells take it up by receptor-mediated endocytosis: LDL binds the LDL receptor, which concentrates in clathrin-coated pits; the resulting vesicle delivers LDL to endosomes, where low pH releases the particle from its receptor. The receptor recycles to the cell surface for reuse, while LDL is delivered to lysosomes where its cholesterol esters are hydrolyzed to free cholesterol. This elegant cycle is the textbook example of receptor-mediated endocytosis, and its disruption causes familial hypercholesterolemia and premature atherosclerosis.

Key Components

• LDL particle: a lipoprotein with a core of cholesterol esters and a surface coat of phospholipids, free cholesterol, and one molecule of apolipoprotein B-100 (ApoB-100).
• LDL receptor: a transmembrane protein whose extracellular domain binds ApoB-100; its cytoplasmic tail carries an NPXY internalization signal recognized by AP2.
• Clathrin-coated pit and AP2 adaptor: concentrate the receptor–ligand complex.
• Endosome acidification: the vacuolar H⁺-ATPase (V-ATPase) lowers endosomal pH, triggering ligand release.
• Lysosomes: degrade LDL; acid lipase releases free cholesterol.
• SREBP pathway: senses cholesterol and regulates LDL receptor and cholesterol synthesis (feedback control).

Mechanism / How It Works

1. Circulating LDL binds the LDL receptor on the cell surface via ApoB-100.
2. The receptor–ligand complexes cluster in clathrin-coated pits (internalization signal binds AP2).
3. The pit invaginates and dynamin pinches off a coated vesicle.
4. The vesicle uncoats and fuses with an early endosome.
5. The V-ATPase acidifies the endosome; at ~pH 5–6, the receptor undergoes a conformational change and releases the LDL particle.
6. The receptor is sorted into recycling tubules and returns to the plasma membrane (a receptor molecule cycles about every 10 minutes over ~100+ trips).
7. LDL remains in the maturing endosome, which becomes a late endosome and fuses with a lysosome.
8. In the lysosome, ApoB is degraded to amino acids and cholesterol esters are hydrolyzed by acid lipase to free cholesterol, which the cell uses for membranes, steroid hormones, and bile acids.
9. Rising free cholesterol activates SREBP-mediated feedback that downregulates LDL receptor synthesis and HMG-CoA reductase (cholesterol synthesis).

Energy and Directionality

Uptake is unidirectional (blood → cell interior) and energy-consuming: GTP (dynamin, Rabs, ARF), ATP (V-ATPase pumping H⁺ into endosomes, motor-based transport). The receptor–ligand dissociation is driven by the pH gradient (low endosomal pH), which the V-ATPase maintains using ATP — a classic example of an ion gradient powering a conformational switch rather than a direct ATP-consuming "unbinding" step.

Experimental Evidence / Technique

• Brown and Goldstein's classic studies (Nobel Prize 1985): fibroblasts from patients with familial hypercholesterolemia (FH) failed to bind, internalize, or degrade LDL, and showed defective feedback suppression of HMG-CoA reductase — dissecting the entire LDL receptor pathway.
• Iodinated (¹²⁵I)-LDL binding and uptake assays: demonstrated saturable, high-affinity, specific binding and receptor-mediated internalization.
• Ammonium chloride / chloroquine treatment: these weak bases neutralize endosomes and block LDL dissociation and delivery — proving acidification is required for the ligand-release step.
• Immunofluorescence / electron microscopy: followed the receptor through coated pits, endosomes, and back to the surface (receptor recycling).

How it works

1. Circulating LDL binds the LDL receptor on the cell surface via ApoB-100.
2. The receptor–ligand complexes cluster in clathrin-coated pits (internalization signal binds AP2).
3. The pit invaginates and dynamin pinches off a coated vesicle.
4. The vesicle uncoats and fuses with an early endosome.
5. The V-ATPase acidifies the endosome; at ~pH 5–6, the receptor undergoes a conformational change and releases the LDL particle.
6. The receptor is sorted into recycling tubules and returns to the plasma membrane (a receptor molecule cycles about every 10 minutes over ~100+ trips).
7. LDL remains in the maturing endosome, which becomes a late endosome and fuses with a lysosome.
8. In the lysosome, ApoB is degraded to amino acids and cholesterol esters are hydrolyzed by acid lipase to free cholesterol, which the cell uses for membranes, steroid hormones, and bile acids.
9. Rising free cholesterol activates SREBP-mediated feedback that downregulates LDL receptor synthesis and HMG-CoA reductase (cholesterol synthesis).

Common confusions

• "The receptor is degraded along with LDL." The receptor is recycled to the surface and reused ~100 times; only the LDL is degraded.
• "LDL is digested in the endosome." LDL is only separated from its receptor in the acidic endosome; degradation happens later in the lysosome.
• "Familial hypercholesterolemia is always a total absence of receptor." It can be reduced receptor number, defective binding, or defective internalization — several molecular classes exist.
• "Statins directly activate the LDL receptor." Statins inhibit cholesterol synthesis; the resulting lower intracellular cholesterol upregulates receptor gene expression via SREBP.
• "Acidification requires no energy." The V-ATPase actively pumps protons using ATP to create the acidic lumen.

Quick review

• LDL + LDL receptor → clathrin-coated pit → coated vesicle → early endosome.
• Low endosomal pH releases LDL; receptor recycles to the surface.
• LDL → late endosome → lysosome; acid lipase frees cholesterol.
• Free cholesterol feedback-inhibits receptor and synthesis (SREBP).
• LDLR mutations → familial hypercholesterolemia; statins exploit this pathway.